Skip to main content

Market Overview

Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings

Share:

Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.

  • Allocetra is a macrophage-reprogramming immunotherapy product, a potential therapy combined with approved immune checkpoint inhibitors for hard-to-treat solid tumors.
  • Under the strategic collaboration, the parties intend to develop and execute pre-clinical programs to investigate the potential synergies between Allocetra and commercially approved checkpoint inhibitor therapies for select solid cancers.
  • Enlivex plans to initiate a controlled, randomized, Phase 2b study in sepsis during the first quarter of 2021.
  • Price Action: ENLV shares are trading 2.81% lower at $13.15 in market trading hours on the last check Monday.
 

Related Articles (ENLV)

View Comments and Join the Discussion!

Posted-In: Solid TumorBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com